Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Accumulated Expenses data on file, last reported at $7.3 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 43.44% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 43.44% YoY), and the FY2025 full-year result was $7.3 million, up 43.44% from the prior year.
• Accumulated Expenses advanced to $7.3 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.3 million in Q4 2025 to a low of $1.1 million in Q2 2021.
• A 5-year average of $3.0 million and a median of $2.7 million in 2025 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 153.5% in 2024, while the deepest fall reached 58.42% in 2024.
• Tracing CADL's Accumulated Expenses over 5 years: stood at $2.1 million in 2021, then grew by 26.29% to $2.6 million in 2022, then declined by 23.8% to $2.0 million in 2023, then soared by 153.5% to $5.1 million in 2024, then jumped by 43.44% to $7.3 million in 2025.
• Business Quant data shows CADL's Accumulated Expenses at $7.3 million in Q4 2025, $2.6 million in Q3 2025, and $1.9 million in Q2 2025.